Literature DB >> 30098853

Cognitive control network dysconnectivity and response to antipsychotic treatment in schizophrenia.

Elyse J Cadena1, David M White1, Nina V Kraguljac1, Meredith A Reid2, Ripu Jindal1, Roland Matthew Pixley1, Adrienne C Lahti3.   

Abstract

To better understand cognitive control impairment in schizophrenia, it is vital to determine the extent of dysfunctional connectivity in the associated fronto-striatal brain network, with a focus on the connections with the anterior cingulate cortex (ACC), prior to the potential confounding effect of medication. It is also essential to determine the effects following antipsychotic medication and the relationship of those effects on psychosis improvement. Twenty-two patients with schizophrenia, initially unmedicated and after a 6-week course of risperidone, and 20 matched healthy controls (HC) performed a fMRI task twice, six weeks apart. We investigated group and longitudinal differences in ACC-related functional connectivity during performance of a Stroop color task as well as connectivity patterns associated with improvement in psychosis symptoms. Unmedicated patients with schizophrenia showed greater functional connectivity between ACC and bilateral caudate and midbrain and lower connectivity with left putamen compared to healthy controls. At baseline, greater functional connectivity between ACC and bilateral putamen predicted subsequent better treatment response. Change in functional connectivity between ACC and left putamen positively correlated with better treatment response. These results suggest that patterns of functional connectivity in fronto-striatal networks can be utilized to predict potential response to antipsychotic medication. Prior to treatment, brain function may be structured with a predisposition that favors or not treatment response.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Anterior cingulate; Antipsychotic medication; Cognitive task; Functional connectivity; Treatment response; Unmedicated

Mesh:

Substances:

Year:  2018        PMID: 30098853      PMCID: PMC7909720          DOI: 10.1016/j.schres.2018.07.045

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  48 in total

1.  Stroop performance in normal control subjects: an fMRI study.

Authors:  Staci A Gruber; Jadwiga Rogowska; Philip Holcomb; Salvatore Soraci; Deborah Yurgelun-Todd
Journal:  Neuroimage       Date:  2002-06       Impact factor: 6.556

2.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.

Authors:  Joseph A Maldjian; Paul J Laurienti; Robert A Kraft; Jonathan H Burdette
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

3.  A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia.

Authors:  Tyler A Lesh; Costin Tanase; Benjamin R Geib; Tara A Niendam; Jong H Yoon; Michael J Minzenberg; J Daniel Ragland; Marjorie Solomon; Cameron S Carter
Journal:  JAMA Psychiatry       Date:  2015-03       Impact factor: 21.596

4.  Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.

Authors:  Meredith A Reid; Luke E Stoeckel; David M White; Kathy B Avsar; Mark S Bolding; N Shastry Akella; Robert C Knowlton; Jan A den Hollander; Adrienne C Lahti
Journal:  Biol Psychiatry       Date:  2010-06-08       Impact factor: 13.382

Review 5.  A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

Authors:  Neil D Woodward; Scot E Purdon; Herbert Y Meltzer; David H Zald
Journal:  Int J Neuropsychopharmacol       Date:  2005-03-23       Impact factor: 5.176

6.  Anterior cingulate cortex activity and impaired self-monitoring of performance in patients with schizophrenia: an event-related fMRI study.

Authors:  C S Carter; A W MacDonald; L L Ross; V A Stenger
Journal:  Am J Psychiatry       Date:  2001-09       Impact factor: 18.112

7.  A generalized form of context-dependent psychophysiological interactions (gPPI): a comparison to standard approaches.

Authors:  Donald G McLaren; Michele L Ries; Guofan Xu; Sterling C Johnson
Journal:  Neuroimage       Date:  2012-03-30       Impact factor: 6.556

8.  Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia.

Authors:  Katherine E Burdick; Joseph F Goldberg; Martin Harrow; Robert N Faull; Anil K Malhotra
Journal:  J Nerv Ment Dis       Date:  2006-04       Impact factor: 2.254

9.  Clinical utility of the risperidone formulations in the management of schizophrenia.

Authors:  Vishal Madaan; Durga P Bestha; Venkata Kolli; Saurabh Jauhari; Roger C Burket
Journal:  Neuropsychiatr Dis Treat       Date:  2011-10-18       Impact factor: 2.570

10.  Time course for antipsychotic treatment response in first-episode schizophrenia.

Authors:  Robin Emsley; Jonathan Rabinowitz; Rossella Medori
Journal:  Am J Psychiatry       Date:  2006-04       Impact factor: 19.242

View more
  9 in total

1.  Ultrastructural evidence for glutamatergic dysregulation in schizophrenia.

Authors:  Rosalinda C Roberts; Lesley A McCollum; Kirsten E Schoonover; Samuel J Mabry; Joy K Roche; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2020-01-31       Impact factor: 4.939

2.  Functional Connectivity of the Striatum in Schizophrenia and Psychotic Bipolar Disorder.

Authors:  Nicole R Karcher; Baxter P Rogers; Neil D Woodward
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-06-12

Review 3.  The role of attention control in complex real-world tasks.

Authors:  Christopher Draheim; Richard Pak; Amanda A Draheim; Randall W Engle
Journal:  Psychon Bull Rev       Date:  2022-02-15

Review 4.  Neuroimaging as a Window Into the Pathophysiological Mechanisms of Schizophrenia.

Authors:  Nina Vanessa Kraguljac; Adrienne Carol Lahti
Journal:  Front Psychiatry       Date:  2021-03-11       Impact factor: 5.435

5.  Changes in corticostriatal connectivity and striatal tissue iron associated with efficacy of clozapine for treatment‑resistant schizophrenia.

Authors:  Annie Blazer; K N Roy Chengappa; William Foran; Ashley C Parr; Charles E Kahn; Beatriz Luna; Deepak K Sarpal
Journal:  Psychopharmacology (Berl)       Date:  2022-04-18       Impact factor: 4.415

6.  Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study.

Authors:  Paola Dazzan; Andrew J Lawrence; Antje A T S Reinders; Alice Egerton; Neeltje E M van Haren; Kate Merritt; Gareth J Barker; Rocio Perez-Iglesias; Kyra-Verena Sendt; Arsime Demjaha; Kie W Nam; Iris E Sommer; Christos Pantelis; W Wolfgang Fleischhacker; Inge Winter van Rossum; Silvana Galderisi; Armida Mucci; Richard Drake; Shon Lewis; Mark Weiser; Covadonga M Martinez Diaz-Caneja; Joost Janssen; Marina Diaz-Marsa; Roberto Rodríguez-Jimenez; Celso Arango; Lone Baandrup; Brian Broberg; Egill Rostrup; Bjørn H Ebdrup; Birte Glenthøj; Rene S Kahn; Philip McGuire
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 7.348

7.  Predicting individual improvement in schizophrenia symptom severity at 1-year follow-up: Comparison of connectomic, structural, and clinical predictors.

Authors:  Akhil Kottaram; Leigh A Johnston; Ye Tian; Eleni P Ganella; Liliana Laskaris; Luca Cocchi; Patrick McGorry; Christos Pantelis; Ramamohanarao Kotagiri; Vanessa Cropley; Andrew Zalesky
Journal:  Hum Brain Mapp       Date:  2020-05-29       Impact factor: 5.038

8.  Disordered directional brain network interactions during learning dynamics in schizophrenia revealed by multivariate autoregressive models.

Authors:  Shahira J Baajour; Asadur Chowdury; Patricia Thomas; Usha Rajan; Dalal Khatib; Caroline Zajac-Benitez; Dimitri Falco; Luay Haddad; Alireza Amirsadri; Steven Bressler; Jeffery A Stanley; Vaibhav A Diwadkar
Journal:  Hum Brain Mapp       Date:  2020-05-21       Impact factor: 5.038

9.  Increased regional homogeneity modulated by metacognitive training predicts therapeutic efficacy in patients with schizophrenia.

Authors:  Xiaoxiao Shan; Rongyuan Liao; Yangpan Ou; Pan Pan; Yudan Ding; Feng Liu; Jindong Chen; Jingping Zhao; Wenbin Guo; Yiqun He
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-03-25       Impact factor: 5.270

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.